Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Total Liabilities: 2022-2024

Historic Total Liabilities for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Dec 2024 value amounting to $175.3 million.

  • Centessa Pharmaceuticals' Total Liabilities rose 32.69% to $146.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.7 million, marking a year-over-year increase of 32.69%. This contributed to the annual value of $175.3 million for FY2024, which is 41.33% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Total Liabilities of $175.3 million as of FY2024, which was up 41.33% from $124.0 million recorded in FY2023.
  • Centessa Pharmaceuticals' Total Liabilities' 5-year high stood at $175.3 million during FY2024, with a 5-year trough of $108.1 million in FY2022.
  • Moreover, its 3-year median value for Total Liabilities was $124.0 million (2023), whereas its average is $135.8 million.
  • Data for Centessa Pharmaceuticals' Total Liabilities shows a peak YoY surged of 41.33% (in 2024) over the last 5 years.
  • Over the past 3 years, Centessa Pharmaceuticals' Total Liabilities (Yearly) stood at $108.1 million in 2022, then increased by 14.67% to $124.0 million in 2023, then surged by 41.33% to $175.3 million in 2024.